Medicine
Emgality 100 mg/1 mL injection
Emgality 100 mg/1 mL injection is a prescription medicine containing Galcanezumab for subcutaneous use, marketed by Eli Lilly, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to…
Key facts
- Active ingredient (INN)
- Galcanezumab
- Brand
- Emgality
- Strength
- 100 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 3 syringes of 1 mL
- Marketing authorisation holder
- Eli Lilly
- Manufacturer
- Eli Lilly
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect EMGALITY from light until use. Do not freeze. EMGALITY may be stored out of refrigeration in the original carton at temperatures up to 30°C (86°F) for up to 7 days. Once stored out of refrigeration, do not place back in the refrigerator. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CD02 Galcanezumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 June 2019
- Identifiers
- RxCUI 2058872, 2058877, 2058885 +3DailyMed set ID 33a147be-233a-40e8-a55e-e40936e28db0NDC 0002-3115Application BLA761063
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 syringe in 1 carton / 1 mL in 1 syringe | 0002-3115-09 | Eli Lilly | 17 June 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Galcanezumab
Clinical summary
Galcanezumab is a prescription medicine indicated in adults for the preventive treatment of migraine, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Galcanezumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GalcanezumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- EMGALITY prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
- Emgality: European public assessment report (EPAR) · European Medicines Agency
Need Emgality 100 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.